Bernstein looks at what Trump’s policy bill means for consumers and retailers
Quantum Genomics SA (PA:ALQGC) has announced that the results of its Phase IIb NEW-HOPE study will be presented in a late-breaking presentation at the American Heart Association (AHA) annual meeting on 10 November 2018. Late-breaking presentations are typically reserved for results that are of high interest or impact and this presentation will help increase the profile of both Quantum Genomics and firibastat with physicians, potential partners and investors. We view it as positive that the trial enrolled much faster than expected and that the results will be presented at AHA in a late-breaking presentation.
Phase IIb hypertension data coming in November
NEW-HOPE is a 256-patient trial that focused enrolment on hypertensive overweight (BMI 25–45kg/m2) patients of multiple ethnic and racial groups, with a primary endpoint of change from baseline in office systolic blood pressure (SBP) at week eight. The company announced in September that the trial had completed enrolment months faster than expected.
To read the entire report Please click on the pdf File Below:
3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads.
Which stock should you buy in your very next trade?
With valuations skyrocketing in 2024, many investors are uneasy putting more money into stocks. Unsure where to invest next? Get access to our proven portfolios and discover high-potential opportunities.
In 2024 alone, ProPicks AI identified 2 stocks that surged over 150%, 4 additional stocks that leaped over 30%, and 3 more that climbed over 25%. That's an impressive track record.
With portfolios tailored for Dow stocks, S&P stocks, Tech stocks, and Mid Cap stocks, you can explore various wealth-building strategies.